Strs Ohio continued to hold its stake in Amedisys Inc. (NASDAQ:AMED) during the second quarter, Holdings Channel reports. The institutional investor owned 20,600 shares of the company’s stock at the end of the second quarter. Strs Ohio’s holdings in Amedisys were worth $1,039,000 as of its most recent SEC filing.
A number of other large investors have also recently added to or reduced their stakes in the company. State Street Corp raised its stake in shares of Amedisys by 6.3% in the first quarter. State Street Corp now owns 686,983 shares of the company’s stock worth $33,211,000 after buying an additional 40,819 shares during the period. Renaissance Technologies LLC raised its stake in shares of Amedisys by 81.1% in the first quarter. Renaissance Technologies LLC now owns 630,901 shares of the company’s stock worth $30,498,000 after buying an additional 282,600 shares during the period. BlackRock Group LTD raised its stake in shares of Amedisys by 5.3% in the first quarter. BlackRock Group LTD now owns 553,056 shares of the company’s stock worth $26,736,000 after buying an additional 27,998 shares during the period. Panagora Asset Management Inc. raised its stake in shares of Amedisys by 155.4% in the first quarter. Panagora Asset Management Inc. now owns 164,272 shares of the company’s stock worth $7,941,000 after buying an additional 99,952 shares during the period. Finally, BlackRock Inc. raised its stake in shares of Amedisys by 7.0% in the first quarter. BlackRock Inc. now owns 123,381 shares of the company’s stock worth $5,964,000 after buying an additional 8,077 shares during the period. 91.45% of the stock is owned by institutional investors.
Amedisys Inc. (NASDAQ:AMED) traded down 0.81% during mid-day trading on Friday, hitting $45.18. The stock had a trading volume of 131,392 shares. Amedisys Inc. has a one year low of $31.16 and a one year high of $55.16. The company has a market cap of $1.52 billion, a PE ratio of 39.53 and a beta of 0.96. The firm’s 50-day moving average price is $47.81 and its 200 day moving average price is $49.84.
Amedisys (NASDAQ:AMED) last issued its quarterly earnings results on Tuesday, August 2nd. The company reported $0.42 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.42. Amedisys had a return on equity of 12.17% and a net margin of 2.78%. The firm earned $360 million during the quarter, compared to analysts’ expectations of $353.07 million. During the same period in the previous year, the business earned $0.43 earnings per share. The firm’s revenue for the quarter was up 14.8% on a year-over-year basis. On average, equities research analysts anticipate that Amedisys Inc. will post $1.69 EPS for the current year.
A number of research analysts recently weighed in on AMED shares. Wells Fargo & Co. reissued a “buy” rating on shares of Amedisys in a report on Sunday, September 11th. Zacks Investment Research lowered shares of Amedisys from a “hold” rating to a “sell” rating in a report on Monday, July 11th. Jefferies Group reissued a “buy” rating on shares of Amedisys in a report on Tuesday, September 6th. Finally, Mizuho lowered shares of Amedisys from a “buy” rating to a “neutral” rating and cut their target price for the company from $57.00 to $55.00 in a report on Wednesday, August 3rd. Seven equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Amedisys has an average rating of “Hold” and a consensus target price of $51.75.
Amedisys Company Profile
Amedisys, Inc (Amedisys) is a provider of home health and hospice services. The Company offers home health services to the chronic, co-morbid, aging American population. The Company operates through three segments: home health, hospice and personal care. The Company’s home health segment delivers a range of services in the homes of individuals recovering from surgery, have a chronic disability or terminal illness or need assistance with completing important personal tasks.
Want to see what other hedge funds are holding AMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amedisys Inc. (NASDAQ:AMED).
Receive News & Ratings for Amedisys Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc. and related companies with MarketBeat.com's FREE daily email newsletter.